Effects of Zoladex in Post-Menopausal Breast Cancer
Author Information
Author(s): A.L. Harris, J. Carmichael, B.M.J. Cantwell, M. Dowsett
Primary Institution: University Department of Clinical Oncology, Regional Radiotherapy Centre, Newcastle General Hospital
Hypothesis
LHRH agonists may have direct antitumor effects in post-menopausal breast cancer.
Conclusion
Zoladex can induce objective responses in post-menopausal breast cancer, likely through peripheral hormone changes.
Supporting Evidence
- Two partial responses and two patients with stable disease were observed in patients with previous hormone therapy.
- Six out of seven patients who received tamoxifen after Zoladex showed a response.
- Oestradiol levels fell significantly after one month of treatment.
Takeaway
Zoladex helps some women with breast cancer by changing hormone levels, which can make the cancer shrink.
Methodology
Twenty-eight post-menopausal patients with advanced breast cancer received monthly Zoladex injections, and their responses were assessed.
Limitations
The study had a small sample size and responses were primarily observed in soft tissues.
Participant Demographics
All participants were post-menopausal women with advanced breast cancer.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website